138 related articles for article (PubMed ID: 9804513)
1. Delivery system for targeted thrombolysis without the risk of hemorrhage.
Byun Y; Yang VC
ASAIO J; 1998; 44(5):M638-41. PubMed ID: 9804513
[TBL] [Abstract][Full Text] [Related]
2. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
Song H; Liang JF; Yang VC
ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
4. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
5. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
7. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
8. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
Liang JF; Song H; Li YT; Yang VC
J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
[TBL] [Abstract][Full Text] [Related]
9. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
Lind SE; Smith CJ
Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of thrombolysis and its clinical application in stroke.
Murray V; Norrving B; Sandercock PA; Terént A; Wardlaw JM; Wester P
J Intern Med; 2010 Feb; 267(2):191-208. PubMed ID: 20175866
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
Liang JF; Li YT; Connell ME; Yang VC
AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
14. Application of "ATTEMPTS" for drug delivery.
Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
[TBL] [Abstract][Full Text] [Related]
15. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
16. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.
Ouriel K; Gray B; Clair DG; Olin J
J Vasc Interv Radiol; 2000 Mar; 11(3):295-8. PubMed ID: 10735422
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
Ferres H
Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
[TBL] [Abstract][Full Text] [Related]
18. New developments in thrombolytic therapy.
Collen D; Gold HK
Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
[TBL] [Abstract][Full Text] [Related]
19. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
Collen D; Stassen JM; Verstraete M
J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
[TBL] [Abstract][Full Text] [Related]
20. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
